Hepatitis A: an epidemiological survey in blood donors, France 2015 to 2017

Gallian, Pierre; Barlet, Valérie; Mouna, Lina; Gross, Sylvie; Lecam, Sophie; Ricard, Céline; Wind, Françoise; Pouchol, Elodie; Fabra, Cécile; Flan, Benoît; Visse, Catherine; Djoudi, Rachid; Couturier, Élisabeth; Valk, Henriette de; Tiberghien, Pierre; Roque–Afonso, Anne–Marie

doi:10.2807/1560-7917.es.2018.23.21.1800237

Cited by 19 publications

(24 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viral NAT screening parameters usually include HIV1/2, HBV and HCV [ 33 , 34 , 35 ]. Depending on local conditions, further screening for hepatitis A virus (HAV) [ 36 ], parvovirus B19 (PB19) [ 37 , 38 ], West Nile virus (WNV) [ 39 , 40 ], dengue virus (DENV) [ 41 ], Zika virus (ZIKV) [ 42 , 43 ] or hepatitis E virus (HEV) [ 44 , 45 ] is required.…”

Section: Safety Of Blood Productsmentioning

confidence: 99%

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Oeller

Laner-Plamberger

Krisch

et al. 2021

IJMS

View full text Add to dashboard Cite

Numerous cell-based therapeutics are currently being tested in clinical trials. Human platelet lysate (HPL) is a valuable alternative to fetal bovine serum as a cell culture medium supplement for a variety of different cell types. HPL as a raw material permits animal serum-free cell propagation with highly efficient stimulation of cell proliferation, enabling humanized manufacturing of cell therapeutics within a reasonable timeframe. Providers of HPL have to consider dedicated quality issues regarding identity, purity, potency, traceability and safety. Release criteria have to be defined, characterizing the suitability of HPL batches for the support of a specific cell culture. Fresh or expired platelet concentrates from healthy blood donors are the starting material for HPL preparation, according to regulatory requirements. Pooling of individual platelet lysate units into one HPL batch can balance donor variation with regard to essential platelet-derived growth factors and cytokines. The increasingly applied pathogen reduction technologies will further increase HPL safety. In this review article, aspects and regulatory requirements of whole blood donation and details of human platelet lysate manufacturing are presented. International guidelines for raw materials are discussed, and defined quality controls, as well as release criteria for safe and GMP-compliant HPL production, are summarized.

show abstract

Section: Safety Of Blood Productsmentioning

confidence: 99%

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Oeller

Laner-Plamberger

Krisch

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…These collaborations have shown to be effective in the 2016–2017 outbreak mostly affecting men who have sex with men (MSM). In the context of this outbreak, we previously reported increased frequency of HAV-RNA-positive blood donors in 2017 compared with 2015 and 2016 [2]. We hereby update this information and report a persistently higher number of HAV-infected blood donors throughout 2018.…”

mentioning

confidence: 57%

Persisting higher prevalence of hepatitis A virus RNA in blood donors, France, 2018

et al. 2019

Self Cite

View full text Add to dashboard Cite

“…RNA curves obtained showed a maximum HAV RNA titer of 3.1 × 10 8 IU/mL whereby peak titers >10 7 IU/mL were common (6/10 donors). Earlier studies had reported an even higher RNAemia of 8.59 × 10 8 IU/ mL (16), but suggested lower typical peak titers (16,17). Although the early phase of infection was characterized by rapid exponential growth and a median estimated HAV doubling time of 17.5 (range 14.1-24.7) hours (Table ), the later phase often showed a more or less pronounced biphasic decrease, resulting in a skewed or shouldered RNA curve.…”

Section: Hav Biomarker Results For Donors Who Showed Seroconversionmentioning

confidence: 94%

Hepatitis A Virus Incidence Rates and Biomarker Dynamics for Plasma Donors, United States

Schoch¹,

Wälti²,

Schemmerer³

et al. 2021

Emerg. Infect. Dis.

View full text Add to dashboard Cite

H epatitis A virus (HAV) is a small, nonenveloped RNA virus belonging to the family Picornaviridae. Its biology and transmission cycle have been reviewed elsewhere (1,2) and are therefore only briefl y introduced. Six genotypes and 1 serotype have been described; genotypes I-III circulating in humans and IV-VI circulating in nonhuman primates. Virions exist in either of 2 forms (3): lipid-associated (main form in blood, also referred to as quasi-enveloped) or truly nonenveloped (main form in stool). Although parenteral transmission has also been reported, the predominant transmission route is the fecal-oral through contact with infected persons or uptake of contaminated food and water. Infection might involve an early, as of yet poorly characterized, extrahepatic replication phase (e.g., in gut epithelial cells [4]); from the gut, virions are then transported through the blood to their primary replication site, the liver. The transmission cycle ends with a transport of viral progeny via the bile to the gut, leading to massive virus shedding in stool (2). Although the course of disease is generally self-limiting, several serious complications can occur, especially in older persons or in combination with risk factors.Since 1995, when the fi rst HAV vaccine was licensed in the United States, the annual US incidence rate of acute hepatitis A has decreased tremendously (1,5). During 2015, the National Notifi able Diseases Surveillance System of the Centers for Disease Control and Prevention (CDC) recorded an annual average of 0.4 cases/100,000 inhabitants (5). However, since 2016, the downward trend has reversed (6). In mid-2016-early 2017, Michigan, California, Kentucky, and Utah began to report local personto-person HAV outbreaks, which have since become a national concern: 38,031 cases affecting 35 states (status as of February 2021) (7). In 2018, the annual US incidence rate was 3.8 cases/100,000 population, and the true rate was estimated to be twice as high because of under-ascertainment and under-reporting (6). The current outbreak is enhanced by the fact that most (≈74%) of US-born adults are susceptible to HAV (8). This pattern is typical for industrialized countries that have good standards of sanitation and hygiene and a history of restrictive (mostly infant-targeted or risk group-targeted) vaccination practices (9). HAV genotype IB has been the most common genotype during this outbreak, whereas before 2017, most cases in the United States involved genotype IA (10).

show abstract

Hepatitis A: an epidemiological survey in blood donors, France 2015 to 2017

Cited by 19 publications

References 14 publications

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Persisting higher prevalence of hepatitis A virus RNA in blood donors, France, 2018

Hepatitis A Virus Incidence Rates and Biomarker Dynamics for Plasma Donors, United States

Contact Info

Product

Resources

About